US 10,947,295 B2Granted

Heterodimers of soluble interferon receptors and uses thereof

AssigneeSanabio, LLC

InventorsJames Arthur Posada, Pamela Smolak

Life of this patent

Estimating the term…

Abstract

The present disclosure provides soluble interferon receptors. The methods of the disclosure can be used to treat or prevent a condition associated with an abnormal immune response.

Claims46

Dependent claims

A heterodimer which binds type I interferons comprising a first polypeptide and a second polypeptide selected from:

(i) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
40 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
43;
(ii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
41 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
42;
(iii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
53 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
55;
and
(iv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
57 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
59;
(v) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
40, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
43, SEQ ID NO:
55, and SEQ ID NO:
59;
(vi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
43, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
40, SEQ ID NO:
53, and SEQ ID NO:
57;
(vii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
42, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
41, SEQ ID NO:
45, and SEQ ID NO:
47;
(viii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
41, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
42, SEQ ID NO:
49, and SEQ ID NO:
51;
(ix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
53, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
43, SEQ ID NO:
55, and SEQ ID NO:
59;
(x) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
55, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
40, SEQ ID NO:
53, and SEQ ID NO:
57;
(xi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
57, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
43, SEQ ID NO:
55, and SEQ ID NO:
59;
(xii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
59, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
40, SEQ ID NO:
53, and SEQ ID NO:
57;
(xiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
45, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
42, SEQ ID NO:
49, and SEQ ID NO:
51;
(xiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
47, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
42, SEQ ID NO:
49, and SEQ ID NO:
51;
(xv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
49, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
41, SEQ ID NO:
45, and SEQ ID NO:
47;
(xvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
51, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
41, SEQ ID NO:
45, and SEQ ID NO:
47;
(xvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
61, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
67, SEQ ID NO:
75, and SEQ ID NO:
82;
(xviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
63, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
65, SEQ ID NO:
73, and SEQ ID NO:
81;
(xix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
65, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
63, SEQ ID NO:
71, and SEQ ID NO:
79;
(xx) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
67, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
61, SEQ ID NO:
69, and SEQ ID NO:
77;
(xxi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
69, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
67, SEQ ID NO:
75, and SEQ ID NO:
82;
(xxii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
71, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
65, SEQ ID NO:
73, and SEQ ID NO:
81;
(xxiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
73, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
63, SEQ ID NO:
71, and SEQ ID NO:
79;
(xxiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
75, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
61, SEQ ID NO:
69, and SEQ ID NO:
77;
(xxv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
77, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
67, SEQ ID NO:
75, and SEQ ID NO:
82;
(xxvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
79, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
65, SEQ ID NO:
73, and SEQ ID NO:
81;
(xxvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
81, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
63, SEQ ID NO:
71, and SEQ ID NO:
79;
(xxviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
82, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
61, SEQ ID NO:
69, and SEQ ID NO:
77;
(xxix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
84, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
89, SEQ ID NO:
97, and SEQ ID NO:
105;
(xxx) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
85, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
87, SEQ ID NO:
95, and SEQ ID NO:
103;
(xxxi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
87, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
85, SEQ ID NO:
93, and SEQ ID NO:
101;
(xxxii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
89, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
84, SEQ ID NO:
91, and SEQ ID NO:
99;
(xxxiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
91, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
89, SEQ ID NO:
97, and SEQ ID NO:
105;
(xxxiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
93, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
87, SEQ ID NO:
95, and SEQ ID NO:
103;
(xxxv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
95, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
85, SEQ ID NO:
93, and SEQ ID NO:
101;
(xxxvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
97, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
84, SEQ ID NO:
91, and SEQ ID NO:
99;
(xxxvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
99, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
89, SEQ ID NO:
97, and SEQ ID NO:
105;
(xxxviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
101, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
87, SEQ ID NO:
95, and SEQ ID NO:
103;
(xxxix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
103, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
85, SEQ ID NO:
93, and SEQ ID NO:
101;
and
(xl) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
105, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
84, SEQ ID NO:
91, and SEQ ID NO:
99.

191 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/109,672Filed 22 Aug 2018 · us provisional application
Priority: 22 Aug 2017
Published: US 2019/0194293 A127 Jun 2019
Granted: 16 Mar 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07K 14/7156
For cytokines; for lymphokines; for interferons: for interferons [IFN]
A61K 38/00
Medicinal preparations containing peptides
C07K 2319/30
Fusion polypeptide: non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached…
C07K
Peptides

Family

Application62/548,737Us provisional application · filed 22 Aug 2017
US 2019/0194293 A1Pre-grant publication · published 27 Jun 2019
US 10,947,295 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

The present disclosure provides soluble interferon receptors. The methods of the disclosure can be used to treat or prevent a condition associated with an abnormal immune response.

A heterodimer which binds type I interferons comprising a first polypeptide and a second polypeptide selected from:

(i) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
40 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
43;
(ii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
41 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
42;
(iii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
53 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
55;
and
(iv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
57 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:
59;
(v) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
40, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
43, SEQ ID NO:
55, and SEQ ID NO:
59;
(vi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
43, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
40, SEQ ID NO:
53, and SEQ ID NO:
57;
(vii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
42, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
41, SEQ ID NO:
45, and SEQ ID NO:
47;
(viii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
41, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
42, SEQ ID NO:
49, and SEQ ID NO:
51;
(ix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
53, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
43, SEQ ID NO:
55, and SEQ ID NO:
59;
(x) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
55, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
40, SEQ ID NO:
53, and SEQ ID NO:
57;
(xi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
57, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
43, SEQ ID NO:
55, and SEQ ID NO:
59;
(xii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
59, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
40, SEQ ID NO:
53, and SEQ ID NO:
57;
(xiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
45, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
42, SEQ ID NO:
49, and SEQ ID NO:
51;
(xiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
47, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
42, SEQ ID NO:
49, and SEQ ID NO:
51;
(xv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
49, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
41, SEQ ID NO:
45, and SEQ ID NO:
47;
(xvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
51, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
41, SEQ ID NO:
45, and SEQ ID NO:
47;
(xvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
61, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
67, SEQ ID NO:
75, and SEQ ID NO:
82;
(xviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
63, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
65, SEQ ID NO:
73, and SEQ ID NO:
81;
(xix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
65, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
63, SEQ ID NO:
71, and SEQ ID NO:
79;
(xx) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
67, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
61, SEQ ID NO:
69, and SEQ ID NO:
77;
(xxi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
69, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
67, SEQ ID NO:
75, and SEQ ID NO:
82;
(xxii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
71, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
65, SEQ ID NO:
73, and SEQ ID NO:
81;
(xxiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
73, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
63, SEQ ID NO:
71, and SEQ ID NO:
79;
(xxiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
75, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
61, SEQ ID NO:
69, and SEQ ID NO:
77;
(xxv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
77, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
67, SEQ ID NO:
75, and SEQ ID NO:
82;
(xxvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
79, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
65, SEQ ID NO:
73, and SEQ ID NO:
81;
(xxvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
81, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
63, SEQ ID NO:
71, and SEQ ID NO:
79;
(xxviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
82, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
61, SEQ ID NO:
69, and SEQ ID NO:
77;
(xxix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
84, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
89, SEQ ID NO:
97, and SEQ ID NO:
105;
(xxx) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
85, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
87, SEQ ID NO:
95, and SEQ ID NO:
103;
(xxxi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
87, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
85, SEQ ID NO:
93, and SEQ ID NO:
101;
(xxxii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
89, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
84, SEQ ID NO:
91, and SEQ ID NO:
99;
(xxxiii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
91, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
89, SEQ ID NO:
97, and SEQ ID NO:
105;
(xxxiv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
93, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
87, SEQ ID NO:
95, and SEQ ID NO:
103;
(xxxv) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
95, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
85, SEQ ID NO:
93, and SEQ ID NO:
101;
(xxxvi) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
97, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
84, SEQ ID NO:
91, and SEQ ID NO:
99;
(xxxvii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
99, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
89, SEQ ID NO:
97, and SEQ ID NO:
105;
(xxxviii) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
101, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
87, SEQ ID NO:
95, and SEQ ID NO:
103;
(xxxix) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
103, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
85, SEQ ID NO:
93, and SEQ ID NO:
101;
and
(xl) a first polypeptide comprising the amino acid sequence of SEQ ID NO:
105, and a second polypeptide comprising the amino acid sequence selected from SEQ ID NO:
84, SEQ ID NO:
91, and SEQ ID NO:
99.

191 more elements

Facts

Application

16/109,672Filed 22 Aug 2018 · us provisional application

Priority

22 Aug 2017

Published

US 2019/0194293 A127 Jun 2019

Granted

16 Mar 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07K 14/7156
For cytokines; for lymphokines; for interferons: for interferons [IFN]
A61K 38/00
Medicinal preparations containing peptides
C07K 2319/30
Fusion polypeptide: non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached…
C07K
Peptides